Evogene
EVGN
21 hedge funds and large institutions have $56.8M invested in Evogene in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
11% more funds holding
Funds holding: 19 → 21 (+2)
1.08% more ownership
Funds ownership: 27.76% → 28.84% (+1.1%)
0% more capital invested
Capital invested by funds: $56.7M → $56.8M (+$36.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$586K |
| 3 |
MCM
Moon Capital Management
New York
|
+$386K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$315K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$276K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
-$774K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$129K |
| 3 |
Barclays
London,
United Kingdom
|
-$53.6K |
| 4 |
MLIC
Mandatum Life Insurance Company
Helsinki,
Finland
|
-$16K |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$137 |
EVGN Hedge Fund Activity: Q1 2016 in Review
21 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2016, worth a combined $56.8M — up 0.06% from $56.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EVGN positions and 1 closed out — a net gain of 2 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $1.1M. The largest seller was Mivtachim The Workers Social Insurance Fund, cutting an estimated $774K.
- 21 institutional investors held Evogene (EVGN) as of Q1 2016, up from 19 in Q4 2015.
- Funds reported $56.8M of Evogene stock for Q1 2016, up 0.06% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q1 2016 and 1 closed out, a net change of +2 holders.
- The largest Evogene buyer in Q1 2016 was JP Morgan Chase, an estimated $1.1M added.
- The largest Evogene seller in Q1 2016 was Mivtachim The Workers Social Insurance Fund, an estimated $774K sold.
Based on aggregated 13F filings for Q1 2016.